Investor Presentation INVESTOR PRESENTATION August 2025 FORWARD-LOOKING STATEMENTS AND NON-GAAP FINANCIAL MEASURES This presentation contains, and our other communications may contain, forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements can be identified by the fact that they do not relate strictly to historical or current facts. Forward-looking statements, written, oral o ...

Second Quarter 2025 Earnings August 6, 2025 Disclaimer Forward-Looking Statements This presentation contains forward-looking statements as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that involve significant risks and uncertainties. All statements other than statements of historical facts are forward-looking statements. These forward-looking statements include information about our possible or assumed future results of ...

Commercial Performance - RYTELO Q2 2025 sales reached $49 million[12] - There was an approximate 17% demand increase for RYTELO in Q2 2025 compared to Q1 2025[14] - Approximately 30% of new RYTELO patients starts are in the 1st and 2nd line of treatment[14] - RYTELO has secured favorable coverage policies for approximately 90% of covered lives[14] - Since approval, approximately 400 new ordering accounts have been added year-to-date[14] Clinical Development - The Phase 3 IMpactMF trial is expected to be 100% enrolled by the end of 2025[11, 22] - An interim analysis of the IMpactMF trial is expected in the second half of 2026, with the final analysis anticipated in the second half of 2028[22] Financial Status - The company's cash and marketable securities totaled $432.6 million as of June 30, 2025[25] - Q2 2025 total operating expenses were $61.5 million[25] - The company anticipates operating expenses in the range of $270 million to $285 million for 2025[25]

Investor Presentation Q2 2025 This presentation should not be relied upon for the purpose of evaluating the performance of the Company or for any other purpose, and neither the Company nor any of its affiliates, directors, officers, partners, employees, agents or advisers nor any other person, shall be liable for any direct, indirect or consequential liability, loss or damages suffered by any person as a result of this presentation or their reliance on any statement, estimate, target, projection or forward- ...

Apitegromab in SMA - Positive Phase 3 trial data showed a 18 point improvement versus placebo in Hammersmith Functional Motor Scale-Expanded (HFMSE) in SMA patients[23] - 30% of apitegromab patients achieved ≥3-point improvement in HFMSE compared to 125% of placebo patients[23] - FDA accepted BLA under Priority Review with a target action date of September 22, 2025[25] - MAA Validated with anticipated EU approval in 2026[14] - The company is initiating Phase 2 OPAL Trial in Q3 to study apitegromab in patients under 2 years old[14, 27] Pipeline Expansion - EMBRAZE trial achieved primary endpoint with positive Phase 2 proof-of-concept in obesity[14] - Apitegromab combined with tirzepatide resulted in a 549% reduction in lean mass loss versus tirzepatide alone[36] - The company is on track to file IND for SRK-439 in 2H 2025[14, 39, 43] Financial Status - The company had $295 million cash as of June 30, 2025[14]

Financial Highlights - Total revenue reached $1.6 billion[8], with a net income of $55 million[8] - Adjusted EBITDA stood at $149 million[8], reflecting a margin expansion of 40 basis points to 9.4%[7, 11] - Cash flow from operations amounted to $160 million[8], resulting in a trailing twelve-month (TTM) free cash flow (FCF) conversion of 125%[7, 8] - The book-to-bill ratio was 1.0x for both the quarter and the trailing twelve months[7, 8] - Funded backlog increased by $111 million to $8.9 billion, marking the highest level since the IPO, with 70% being funded[11] Revenue Analysis - Q2 2025 total revenue was $1,584 million[13], a decrease of 5% compared to Q2 2024[13, 17] - Excluding the confidential contract, total revenue increased by 13% and organic revenue grew by 8%[7, 17] Segment Performance - Federal Solutions revenue reached $805 million[19], a decrease of 19% from the prior year period[19, 22], but grew by 11% excluding the confidential contract[19, 22] - Critical Infrastructure revenue increased by 14% to $779 million[21] - Federal Solutions adjusted EBITDA was $67 million[19], while Critical Infrastructure adjusted EBITDA was $82 million[21], a 73% increase from the prior year period[21, 22] Strategic Initiatives - Parsons acquired Chesapeake Technology International (CTI) for $89 million[31, 33], enhancing its position in electronic warfare, cyber, and autonomous systems[7, 11] - The company secured approximately $11 billion worth of contract wins that have not yet been booked into backlog[11] FY25 Guidance - The company increased its FY25 revenue guidance to $6.48 billion - $6.68 billion[37] - Adjusted EBITDA guidance was raised to $595 million - $635 million[37] - Cash flow from operations guidance was increased to $400 million - $440 million[37]

Financial Performance - Royalty Pharma's Portfolio Receipts increased by 20% year-over-year to $727 million in Q2 2025[8, 28] - Royalty Receipts grew by 11% year-over-year to $672 million in Q2 2025[8, 28] - The company repurchased 8 million shares for $277 million in Q2 2025, bringing the total for H1 2025 to $1 billion (31 million shares)[8] - Adjusted EBITDA was $633 million, representing 87.1% of Portfolio Receipts in Q2 2025[28] - Portfolio Cash Flow was $641 million, representing 88.2% of Portfolio Receipts in Q2 2025[28] Capital Allocation and Guidance - Capital Deployment totaled $595 million in Q2 2025[8, 28] - Full year 2025 Portfolio Receipts guidance is $3,050 million to $3,150 million, excluding future transactions, representing approximately 9% to 12% growth[8, 35] - Operating and professional costs are expected to be approximately 9% to 9.5% of Portfolio Receipts for FY 2025[8, 35] Revolution Medicines Partnership - Royalty Pharma entered into a funding partnership with Revolution Medicines for up to $2 billion[15, 16] - This includes up to $1.25 billion for a royalty on daraxonrasib and up to $750 million in senior secured debt[18] - The company projects multi-blockbuster sales potential and an IRR in the teens for daraxonrasib[18]

Financial Performance & Outlook - The company increased its 2025 enterprise outlook to mid- to high single-digit growth in Adjusted EBITDA, excluding catastrophes[12,14] - The company is approaching 10% growth in Adjusted EPS, excluding catastrophes[12,14] - The company generated $298 million in cash[12] - The company returned $209 million to shareholders[12] - The company expects share repurchases of $250-$300 million[65] Global Housing - Global Housing Adjusted EBITDA, excluding catastrophes, increased by 25% in the first half of 2025, reaching $513 million[29] - Global Housing Adjusted EBITDA, excluding catastrophes, increased 18% in Q2 2025, reaching $244 million[57] - Global Housing's combined ratio, excluding prior year development, was 87% in the first half of 2025[31] Global Lifestyle - Global Lifestyle Adjusted EBITDA increased 6% in Q2 2025, or 7% on a constant currency basis[55,58] - Connected Living Adjusted EBITDA increased 9% in Q2 2025, or 11% on a constant currency basis[55,58]

1 Safe Harbor Certain statements in this material, other than statements of historical or current fact, are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act, and Section 21E of the Exchange Act. These statements include, but are not limited to, LivaNova's plans, objectives, strategies, financial performance and outlook, trends, the amount and timing of future cash distributions, prospects or future events, and involve ...

EVE-100 DESIGN EVOLUTION eVTOL DESIGN REFINEMENTS ENHANCE PASSENGER EXPERIENCE, IMPROVE OPERATIONAL EFFICIENCY AND SAFETY A U G U S T 6 , 2 0 2 5 This information belongs to Eve and cannot be used or reproduced without written permission from the Company. 2 Q 2 5 E V E U P D A T E This information belongs to Eve and cannot be used or reproduced without written permission from the Company. 2 2 • Wheeled taxing-gear option • Re-designed and more aerodynamic wing • Optimized cabin interior with lightweight sea ...